{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Sonnet BioTherapeutics Holdings, Inc."},"Symbol":{"label":"Symbol","value":"SONN"},"Address":{"label":"Address","value":"100 OVERLOOK CENTER,SUITE 102, PRINCETON, New Jersey, 08540, United States"},"Phone":{"label":"Phone","value":"+1 609 375-2227"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others."},"CompanyUrl":{"label":"Company Url","value":"https://www.sonnetbio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"John K. Cini","title":"Chief Scientific Officer"},{"name":"Manuel Dafonseca","title":"Head-Clinical Operations"},{"name":"Pankaj Mohan","title":"Chairman, President & Chief Executive Officer"},{"name":"Richard T. Kenney","title":"Chief Medical Officer"},{"name":"Susan Dexter","title":"Chief Technical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}